Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ulcerative colitis for greater than/equal to 3 months.~* Moderate to severe active ulcerative colitis~* Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.~Exclusion Criteria:~* Pregnant or breastfeeding~* Clinical findings suggestive of Crohn's Disease~* History of bowel surgery within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06651600 Drug Dose Level 1 (Type: EXPERIMENTAL): Delivered orally for 8 weeks
- PF-06651600 Drug Dose Level 2 (Type: EXPERIMENTAL): Delivered orally for 8 weeks
- PF-06651600 Drug Dose Level 3 (Type: EXPERIMENTAL): Delivered orally for 8 weeks.
- PF-06651600 Placebo (Type: PLACEBO_COMPARATOR): Delivered orally for 8 weeks.
- PF-06700841 Drug Dose Level 1 (Type: EXPERIMENTAL): Delivered orally for 8 weeks
- PF-06700841 Drug Dose Level 2 (Type: EXPERIMENTAL): Delivered orally for 8 weeks.
- PF-06700841 Drug Dose Level 3 (Type: EXPERIMENTAL): Delivered orally for 8 weeks.
- PF-06700841 Placebo (Type: PLACEBO_COMPARATOR): Delivered orally for 8 weeks.
- PF-06651600 Drug Dose Level 4 (Type: EXPERIMENTAL): Delivered orally for 24 weeks.
- PF-06700841 Drug Dose Level 4 (Type: EXPERIMENTAL): Delivered orally for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).